1. Market Research
  2. > Pharmaceutical Market Trends
  3. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Denmark

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Denmark
DENMARK 1
HEALTHCARE SYSTEM1
Facts and Figures1
Market Indicators2
Provision and Funding4
Healthcare System4
Healthcare Funding5
Provision of Care5
Private Insurance6
PRICING6
Prescription Drugs6
Generic Drugs6
Hospital Drugs7
Pricing Regulations7
Actual Prices8
Tenders8
OTC Drugs9
REIMBURSEMENT9
Admission to Reimbursement9
Application Process9
Decision Making10
General Reimbursement11
Individual Reimbursement12
Reimbursement Categories12
Reimbursement Prices12
Multisource Products12
Single Source Products13
Hospital Reimbursement13
Hospital Formularies13
Medicine Council14
Council for the Use of High-Cost Hospital Medicines (RADS)16
The Co-ordination Council for the Use of Hospital Medicines (KRIS)19
Hospital Funding21
Changes in Reimbursement Status22
Reimbursement List Updates22
Reimbursement Reassessments22
New Presentations and Indications27
Changes in Reimbursement Prices 28
Price Changes28
Primary Care Price Cap Agreement28
Fortnightly Price List29
PHARMACOECONOMICS30
Pharmacoeconomic Requirements30
Retail Drugs30
Hospital Drugs30
PRICE BUILD UP 31
Wholesalers31
Margins31
Background31
Retail Pharmacies32
Margins32
Discounts32
Background 33
Pharmacy Modernisation34
E-pharmacy 36
Dose Dispensing37
Dispensing Doctors37
Sales Tax37
COST CONTAINMENT37
Industry Paybacks37
Promotional Costs37
Patient Co-payments38
Pharmaceuticals38
Healthcare39
Supplementary Insurance 40
Prescribing Controls40
ORDIPRAX40
Medicine Consultants41
National Prescribing Guidelines41
Regional Prescribing Guidelines41
National Prescribing Advice42
National Clinical Guidelines42
Regional Treatment Pathways43
Reimbursement Status43
RADS and KRIS43
Generics43
Substitution44
Rx-to-OTC Switches44
Status Changes44
Two-year Period of Pharmacy-only Sales45
Liberalised OTC Sales45
Direct Patient Access to OTCs46
OTC Market46
Parallel Trade 46
FUTURE DEVELOPMENTS47
Outlook47
NAMES and ADDRESSES48

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the ...

PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.